Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/1996
06/04/1996US5523313 Hypotensive agents; cardiotonic agents; inhibitors of neutral metalloendopeptidases; vasodilation; heart failure and renal insufficiency
06/04/1996US5523309 Benzofuran pharmaceutical compounds
06/04/1996US5523306 Amino acid derivatives cyclized at the C-terminal
06/04/1996US5523305 Analgesics
06/04/1996US5523304 Reversal of multi-drug resistance by tetraarylethylenes
06/04/1996US5523303 Antiulcer and -secretory agents; gastric h+k+ atpase inhibitors; nontoxic; oximes derivatives
06/04/1996US5523301 Topically applying adrenergic blocking agent to eye to maintain retinal nerve fiber layer thickness, increase axoplasmic flow and decrease optic disc cupping and pallor; prophylaxis
06/04/1996US5523299 Administering in treatment of psychotic disorders
06/04/1996US5523298 Used to induce labor, abortion, menstruation, and againsts hormonal irregularities
06/04/1996US5523297 Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
06/04/1996US5523296 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
06/04/1996US5523295 Administering silicon compounds to inhibit interaction of aluminum compounds and neurofilament proteins, for prevention or reversal of plaque formation
06/04/1996US5523294 Di-lysoganglioside derivatives
06/04/1996US5523289 Renin inhibitor
06/04/1996US5523288 Concurrently administering protein product and polymyxin b to treat infections caused by escherichia, providencia or pseudomonas species
06/04/1996US5523099 Stability, reduced sweetness, appropriate viscosity, non-crystallizing and less fermentabiity; foods, beverages, cosmetics and drugs
06/04/1996US5523094 Aqueous mixture of alfuzosin, organic solvent and absorption promoter
06/04/1996US5523087 Containing phytoestrogen, phosphatidyl choline, sitosterol,damiana leaf dry extract, vitamins, minerals, carrier
06/04/1996US5523082 Dissolving bromocriptine(or salt) in methanol, dilution with mixture of water and polyvinyl pyrrolidone, freeze drying the mixture, then redissolving residue in solution of polyoxyethylene glycol and unsaturated carboxylic acid
06/04/1996US5523075 Materials and methods utilizing a temporary visual indicator
06/04/1996EP0722440A4 Pyrimidinyl-glutamic acid derivatives
06/04/1996CA2019863C Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
06/03/1996CA2164246A1 Aryloxypropanolamine beta 3 adrenergic agonists
06/02/1996CA2163490A1 Pyrrole derivatives
06/02/1996CA2161209A1 3-<1,2,3,6-tetrahydro-<1-alkylenearyl>-4-pyridinyl>- and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-ht1f agonists
06/02/1996CA2137472A1 Freeskin
06/02/1996CA2137105A1 Pharmaceutical compositions for topical application
05/1996
05/31/1996CA2163392A1 Oligoribonucleotides with amide backbone
05/30/1996WO1996016169A1 Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
05/30/1996WO1996016084A2 A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
05/30/1996WO1996016076A1 Androstane and pregnane series for allosteric modulation of gaba receptor
05/30/1996WO1996016068A1 Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them
05/30/1996WO1996016065A1 Heterocyclic compounds and their preparation and use
05/30/1996WO1996016063A1 Morphine and codeine derivatives for use in therapy
05/30/1996WO1996016060A1 Enterokinetic benzamide
05/30/1996WO1996016059A1 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
05/30/1996WO1996016058A1 Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
05/30/1996WO1996016056A1 Piperazine, piperidine & tetrahydropyridine derivatives useful as 5-ht1 receptor agonists
05/30/1996WO1996016055A1 A new physically stable solid form of a fluoroquinolone
05/30/1996WO1996016052A2 Certain substituted 1-aryl-3-piperazin-1'-yl propanones
05/30/1996WO1996016051A1 Hypolipidemic benzothiazepines
05/30/1996WO1996016049A1 OXAZOLE DERIVATIVES AS ANTAGONISTS OF α-1C ADRENERGIC RECEPTORS
05/30/1996WO1996016048A1 Microbicidal triazolyl derivatives
05/30/1996WO1996016046A2 Novel benzyl pyrimidines
05/30/1996WO1996016042A1 Antibacterial dibenzimidazole derivatives
05/30/1996WO1996016041A1 Heteroaryl-substituted deoxy glycero-phosphoethanolamines
05/30/1996WO1996016040A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
05/30/1996WO1996016037A1 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
05/30/1996WO1996016036A1 18-nor-vitamin d compounds
05/30/1996WO1996016035A1 18,19-dinor-vitamin d compounds
05/30/1996WO1996016031A1 Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
05/30/1996WO1996016027A1 Matrix metalloprotease inhibitors
05/30/1996WO1996015815A1 Microcapsules, method of making and their use
05/30/1996WO1996015810A1 Monofunctional and/or polyfunctional polylysine conjugates
05/30/1996WO1996015809A2 Process for the preparation of a pharmacologically active chemical combination
05/30/1996WO1996015798A2 Use of bioassimilable boron compounds for the control of subviral pathogenic agents
05/30/1996WO1996015797A1 Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
05/30/1996WO1996015796A1 The use of levoglucosan for the treatment of infectious or inflammatory conditions
05/30/1996WO1996015795A1 Compositions containing lazaroids and their use for preventing adhesions
05/30/1996WO1996015794A1 Compositions and methods for contraception and for treatment of benign gynecological disorders
05/30/1996WO1996015793A1 Percutaneously absorbable preparation
05/30/1996WO1996015792A1 Methods for treating or preventing alzheimer's disease using substituted 1-aryl-3-piperazin-1'-yl propanones
05/30/1996WO1996015791A2 Use of substituted aryl-morpholino-, thiomorpholino- or piperazino-propanones for the treatement of prevention of alzheimer'disease
05/30/1996WO1996015790A1 Lubeluzole intravenous solutions
05/30/1996WO1996015789A1 Non-peptidic surrogates of arg-gly-asp sequence and use
05/30/1996WO1996015788A1 Use of amino-isoxazolidone compounds for improvement of implicit memory
05/30/1996WO1996015787A1 Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
05/30/1996WO1996015786A2 Oral compositions containing ondansetron
05/30/1996WO1996015785A1 Freeze-dried ondansetron compositions
05/30/1996WO1996015784A3 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance
05/30/1996WO1996015784A2 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance
05/30/1996WO1996015782A1 A method for treating vascular headaches
05/30/1996WO1996015781A1 Use of nitric oxide-releasing agents for reducing metastasis risk
05/30/1996WO1996015778A1 Polynucleotide compositions
05/30/1996WO1996015776A1 Percutaneously absorbable patch
05/30/1996WO1996015775A1 Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
05/30/1996WO1996015774A1 Methods and apparatus for making liposomes containing hydrophobic drugs
05/30/1996WO1996015771A1 Prophylactic and therapeutic treatment of skin sensitization and irritation
05/30/1996WO1996015761A1 Cosmetic compositions in stick form
05/30/1996WO1996015669A1 Prophylactic treatment of allergic contact dermatitis
05/30/1996WO1996011005A3 Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
05/30/1996WO1996007410A3 Depolarizing skeletal muscle relaxants
05/30/1996DE4442257A1 Use of sparsomycin in 5- fluoro-uracil therapy of carcinoma
05/30/1996DE4442097A1 Verwendung halogenierter ß-Carboline als Modellsubstanzen zur Erzeugung neurodegenerativer Erkrankungen Use of halogenated ß-carbolines as model substances for the production of neurodegenerative diseases
05/30/1996DE4441763A1 Treatment of hepatic encephalopathy with salt of branched aminoacid
05/30/1996DE19541284A1 Verfahren zur Immunmodulation Methods for immunomodulation
05/30/1996CA2206876A1 18,19-dinor-vitamin d compounds
05/30/1996CA2206873A1 18-nor-vitamin d compounds
05/30/1996CA2205969A1 Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
05/30/1996CA2205920A1 Prophylactic treatment of allergic contact dermatitis
05/30/1996CA2205919A1 Androstane and pregnane series for allosteric modulation of gaba receptor
05/30/1996CA2205897A1 Compositions and methods for contraception and for treatment of benign gynecological disorders
05/30/1996CA2205860A1 Prophylactic and therapeutic treatment of skin sensitization and irritation
05/30/1996CA2205665A1 Matrix metalloprotease inhibitors
05/30/1996CA2205661A1 Piperazine, piperidine & tetrahydropyridine derivatives useful as 5-ht1 receptor agonists
05/30/1996CA2205606A1 Lubeluzole intravenous solutions
05/30/1996CA2205586A1 Certain substituted 1-aryl-3-piperazin-1'-yl propanones
05/30/1996CA2205540A1 A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
05/30/1996CA2205523A1 6-methoxy-1 h-benzotriazole-5-carboxamide derivatives, their production processes and pharmaceutical compositions containing them
05/30/1996CA2205504A1 Certain substituted 1-aryl-3-piperazin-1'-yl propanones
1 ... 6912 6913 6914 6915 6916 6917 6918 6919 6920 6921 6922 6923 6924 6925 6926 6927 6928 6929 6930 6931 6932 ... 7860